News

GSK paid smaller companies to delay generic versions of paroxetine, says fair trade body

BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f2566 (Published 22 April 2013) Cite this as: BMJ 2013;346:f2566
  1. Clare Dyer
  1. 1BMJ

The UK Office of Fair Trading (OFT) has accused GlaxoSmithKline of breaching competition law and abusing its dominant market in the supply of an antidepressant.

The competition watchdog said that it would investigate a series of deals the United Kingdom’s biggest drug maker made between 2001 and 2004 with three smaller companies that wanted to market cheaper generic versions of GSK’s blockbuster drug paroxetine (which it markets as Seroxat).

The OFT alleges that GSK accused the generic manufacturers of infringeing its patents and, to settle the disputes, struck so called “pay for delay” deals, in …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe